MOLECULAR MECHANISMS OF BODY WEIGHT REGULATION AS TARGETS FOR PATHOGENETIC THERAPY OF OBESITY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The prevalence of obesity and associated diseases is comparable to the scale of the epidemic. Along with lifestyle changes, pharmacotherapy is an integral element of the programme of management of patients with obesity. Targets of these drugs are the key pathways of the central nervous system, involved in the regulation of energy exchange. This article describes the basic mechanisms of the central and peripheral regulation of appetite, the modern principles of drug therapy of obesity and characteristic of the basic drugs.

Full Text

Restricted Access

About the authors

Tatiana Ivanovna Romantsova

I.M. Sechenov First Moscow State Medical University

Email: romantsovatatiana@rambler.ru
MD, Professor of the Department of Endocrinology 11999, Moscow, 28-2 Trubetskaya St

References

  1. Ng M., Fleming T., Robinson M., Thomson B., Graetz N., Margono C., Mullany E.C., Biryukov S. et al. Global, regional and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766-81.
  2. World Health Organization Media Centre. Fact Sheet: Obesity and Overweight. World Health Organization: Geneva, 2013.
  3. Dhurandhar E.J., Keith S.W. The aetiology of obesity beyond eating more and exercising less. Best Pract. Res. Clin. Gastroenterol. 2014;28(4):533-44.
  4. Jones B.J., Bloom S.R. The new era of drug therapy for obesity: the evidence and the expectations. Drugs. 2015;75(9):935-45.
  5. Meek T.H., Schwartz M.W. Neurobiology of food intake in health and disease. Nat. Rev. Neurosci. 2014;15(6):367-78.
  6. Gautron L., Elmquist J.K., Williams K.W. Neural control of energy balance: translating circuits to therapies. Cell. 2015;161(1):133-45.
  7. Kim G.W., Lin J.E., Blomain E.S., Waldman S.A. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin. Pharmacol. Ther. 2014;95(1):53-66.
  8. Richard D. Cognitive and autonomic determinants of energy homeostasis in obesity. Nat. Rev. Endocrinol. 2015;11(8):489-501.
  9. Begg D.P., Woods S.C. The endocrinology of food intake. Nat. Rev. Endocrinol. 2013;9(10):584-97.
  10. Hussain S.S., Bloom S.R. The regulation of food intake by the gut-brain axis: implications for obesity. Int. J. Obes. (Lond). 2013;37(5):625-33.
  11. Berthoud H.-R. Metabolic and hedonic drives in the neural control of appetite: Who's the boss? Curr. Opin. Neurobiol. 2011;21(6):888-96.
  12. Volkow N.D., Wang G.J., Baler R.D. Reward, dopamine and the control of food intake: implication for obesity. Trends Cogn. Sci. 2011;15(1):37-46.
  13. Kenny P.J. Reward mechanisms in obesity: new insights and future directions. Neuron. 2011;69(4):664-79.
  14. Alonso-Alonso M., Woods S.C., Pelchat M., Grigson P.S., Stice E., Farooqi S., Khoo C.S., Mattes R.D., Beauchamp G.K. Food reward system: current perspectives and future research needs. Nutr. Rev. 2015;73(5):269-307.
  15. Kringelbach M.L. The pleasure of food: underlying brain mechanisms of eating and other pleasures. Flavor. 2015;4(20):1-12.
  16. Apovian C.M., Aronne L.J., Bessesen D.H., McDonnell M.E., Murad M.H., Pagotto U., Ryan D.H., Still C.D. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2015;100(2):342-62.
  17. William T., Cefalu W.T., Bray G.A. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors' expert forum. Diabetes Care. 2015;38:1567-82.
  18. Xia Y., Kelton C.M.L., Guo J.J., Bian B., Heaton P.C. Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010. Obesity. 2015;23(8):1721-8.
  19. Sharma M.K., Murumkar P.R., Barmade M.A., Giridhar R., Yadav M.R. A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin. Ther. Pat. 2015;10:1-24.
  20. Khorassani F.E., Misher A., Garris S. Past and present of antiobesity agents: focus on monoamine modulators. Am. J. Health Syst. Pharm. 2015;72(9):697-706.
  21. Fletcher P.C., Napolitano A., Skeggs A., Miller S.R., Delafont B., Cambridge V.C., de Wit S., Nathan P.J., Brooke A., O'Rahilly S., Farooqi I.S., Bullmore E.T. Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum. J. Neurosci. 2010;30(43):14346-55.
  22. James W.P., Caterson I.D., Coutinho W., Finer N., Van Gaal L.F., Maggioni A.P., Torp-Pedersen C., Sharma A.M., Shepherd G.M., Rode R.A., Renz C.L.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 2010;363(10):905-17.
  23. Hayes J.F., Bhaskaran K., Batterham R., Smeeth L., Douglas I. The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. Int. J. Obes. (Lond). 2015;39(9):1359-64.
  24. Аметов А.С. Отчет о программе ВЕСНА. Эффективное лечение ожирения - путь борьбы с эпидемией Diabetus mellipidus. Эффективная фармакотерапия. Эндокринология. Спецвыпуск. 2013; 7-12.
  25. Dedov I., Melnichenko G., Romantsova T., Zhuravleva M. Preliminary analysis of the PRIMAVERA Study: reduxine safety monitoring in patients with alimentary obesity. 17th European Congress of Endocrinology, 16-20 May 2015. Endocrine Abstracts, OC11.5
  26. Costantino L., Barlocco D. New perspectives on the development of antiobesity drugs. Future Med. Chem. 2015;7(3):315-36.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies